Colorectal Cancer, Melanoma, Non-small Cell Lung Cancer
Conditions
Keywords
BESPOKE, circulating tumor DNA
Brief summary
This is a prospective data collection study of patients with advanced solid tumors who will receive standard of care immunotherapy (IO) and will be monitored with SIGNATERA™ testing. SIGNATERA™ test will be performed at baseline and during routine care. The test results will be part of assessing tumor response. The correlation between SIGNATERA™ test results and subsequent treatment decisions will be examined to compare actual treatment delivered against treatment decisions potentially impacted by SIGNATERA™ results. Treatment administered, tumor assessment results, time to progression, overall survival, physician questionnaires, and patient-reported outcomes will be collected/recorded.
Detailed description
Primary Objective: ● To examine the impact of SIGNATERA™ on clinical decision-making regarding continuation, discontinuation, escalation, or de-escalation of immunotherapy. Secondary Objective: ● To prospectively evaluate the utility of SIGNATERA™ as a tool to detect early evidence of response or progression in patients with advanced solid tumors receiving immune checkpoint inhibitors.
Interventions
None listed
Sponsors
Natera, Inc.
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Prospective Inclusion Criteria: 1. Male or female patients 18 years of age or older at the time of signing informed consent form (ICF) 2. Any patient with documented metastatic or locally advanced, unresectable cancer of the types within the following cohorts: 1. Melanoma 2. Non-small cell lung cancer 3. Colorectal cancer 3. Patients must be clinically eligible and planned to receive therapy with an anti-neoplastic agent that works by immune checkpoint blockade, anti-PD-1, anti-CTLA-4, or anti-PD-L1: 1. Pembrolizumab (Keytruda) 2. Nivolumab (Opdivo) 3. Ipilimumab (Yervoy) 4. Durvalumab (Imfinzi) 5. Cemiplimab (Libtayo) 6. Atezolizumab (Tecentriq) 7. Avelumab (Bavencio) 4. Patients must have measurable disease according to RECIST criteria, and at least one lesion that can be accurately measured in at least one dimension as \>10 mm. 5. Patients must be able to follow study visit schedule and willing to provide up to 20 mL of peripheral blood samples at the indicated time points 6. ECOG Performance status 0,1, or 2 7. Able to read, understand and provide written informed consent 8. Willing and able to comply with the study requirements 9. Selected by their HCP to receive SIGNATERA testing according to the current evidence-informed schedule as part of their routine of practice Prospective
Exclusion criteria
1. Female patients that are pregnant 2. History of bone marrow or organ transplant 3. Medical condition that would place the patient at risk as a result of blood donation, such as bleeding disorder 4. Serious medical condition that may adversely affect ability to participate in the study 5. Has initiated Immunotherapy Control Arm Inclusion Criteria: 1. Male or female patients 18 years of age or older at the time of signing informed consent form (ICF) 2. Any patient with documented metastatic or locally advanced, unresectable cancer of the types within the following cohorts: 1. Melanoma 2. Non-small cell lung cancer 3. Colorectal cancer 3. Patients must be clinically eligible and planned to receive therapy with an anti-neoplastic agent that works by immune checkpoint blockade, anti-PD-1, anti-CTLA-4, or anti-PD-L1: 1. Pembrolizumab (Keytruda) 2. Nivolumab (Opdivo) 3. Ipilimumab (Yervoy) 4. Durvalumab (Imfinzi) 5. Cemiplimab (Libtayo) 6. Atezolizumab (Tecentriq) 7. Avelumab (Bavencio) 4. Patients must have measurable disease according to RECIST criteria, and at least one lesion that can be accurately measured in at least one dimension as \>10 mm. 5. Patients must be able to follow study visit schedule and willing to provide up to 20 mL of peripheral blood samples at the indicated time points 6. ECOG Performance status 0,1, or 2 7. Able to read, understand and provide written informed consent 8. Willing and able to comply with the study requirements 9. Selected by their HCP to receive SIGNATERA testing according to the current evidence-informed schedule as part of their routine of practice Control Arm
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Examine the impact of SIGNATERA on treatment decisions on tumor assessment timepoints after initiation of immunotherapy | 2 years | Percent of patients who have their immunotherapy treatment regimen changed due to post-treatment SIGNATERA ctDNA test result |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Determine overall survival according to ctDNA change | 2 years | Compare overall survival, defined as the duration of time between enrollment and death for any reason, between groups determined by change in ctDNA |
| Determine response rate according to ctDNA change in cases with progression of disease on first or second tumor assessment and who continue treatment. | 2 years | Compare percentage of patients that experience partial or complete response during the study, between groups determined by change in ctDNA |
| To determine progression free survival according to ctDNA change in cases who achieve stable disease on first tumor assessment. | 2 years | Compare progression free survival between groups determined by change in ctDNA |
| To determine duration of response according to ctDNA change in cases who achieve partial response or complete response as best overall response. | 2 years | Compare duration of response, defined as the length of time from initial response to disease progression, between groups determined by change in ctDNA |
| To determine progression free survival according to ctDNA change | 2 years | Compare progression free survival, defined as the duration of time between enrollment and an increase in severity of disease as determined by patient's treating physician, between groups determined by change in ctDNA |
| Determine the impact of SIGNATERA on the confidence in immunotherapy treatment decisions based on the number of patients in which treating physician reports SIGNATERA made them more confident in immunotherapy treatment regimen | 2 years | Percent of patients whose treating physician reported that SIGNATERA result made them more confident in selected immunotherapy treatment regimen |
| Determine the impact of SIGNATERA in informing immunotherapy treatment decisions | 2 years | Percent of patients whose immunotherapy treatment regimen was changed as a result of SIGNATERA and/or whose treating physician reported that SIGNATERA result made them more confident in selected immunotherapy treatment regimen |
| Determine the impact of SIGNATERA on patient reported outcomes | 2 years | Assess patient anxiety levels and wellbeing in patients receiving SIGNATERA ctDNA test results. Patient responses to patient reported outcome questionnaires: EORTC QLQ-C30 Assess if SIGNATERA makes patients feel that they are receiving the right treatment and determine if patients will continue to use Signatera in the future to monitor their cancer. |
| To determine percentage of patients with at least 6 months of durable clinical response according to ctDNA change in patients who achieve at least partial response on best tumor assessment. | 2 years | Among all patients that are clinically identified to experience partial or complete response, percentage that have at least 6 months durable clinical response as determined by ctDNA change |
Countries
United States
Outcome results
None listed